Acrivastine + Pseudoephedrine

Generic Medicine Info
Indications and Dosage
Allergic rhinitis
Adult: Each cap contains acrivastine 8 mg and pseudoephedrine HCl 60 mg: ≥12 yr 1 cap 4-6 hrly. Max: 4 cap/day.
Renal Impairment
CrCl ≤48 mL/min: Contraindicated.
Hepatic Impairment
No dosage adjustment needed.
Hypersensitivity to triprolidine. Severe HTN or coronary artery disease; renal impairment (CrCl ≤48 mL/min). Concomitant use w/ pseudoephedrine-containing products and MAOIs w/ or w/in 14 days.
Special Precautions
Patients w/ heart disease, HTN, hyperthyroidism, diabetes, elevated intra-ocular pressure and prostatic enlargement. Elderly. Pregnancy and lactation.
Adverse Reactions
CNS depression, sleep disturbance, hallucinations, skin rashes, w/ or w/o irritation.
Symptoms: Restlessness, convulsions, irritability, palpitations, tremor, HTN and difficulty w/ micturition. Management: Emptying the stomach by gastric lavage, or use acid diuresis or dialysis to accelerate the elimination of pseudoephedrine.
Drug Interactions
May increase BP w/ antihypertensive agents, TCA or other sympathomimetic agents (e.g. decongestants, appetite suppressants and amfetamine-like psychostimulants). May reverse the antihypertensive effect of α- and β-adrenergic blockers, betanidine, guanethidine, bretylium, methyldopa and debrisoquine.
Potentially Fatal: Increased BP w/ pseudoephedrine-containing products and MAOIs.
Lab Interference
Pseudoephedrine may cause false-positive result w/ urine detection of amfetamine.
Description: Acrivastine is a non-sedating antihistamine that is structurally related to triprolidine. It provides symptomatic relief by competitively blocking H2-receptor. Pseudoephedrine is both an α-and β-adrenergic receptor agonist. It causes vasoconstriction via direct stimulation of α-adrenergic receptors of the resp mucosa. It also directly stimulates β-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility.
Absorption: Both are readily absorbed from the GI tract. Time to peak plasma concentration: Acrivastine: Approx 1.3 hr; Pseudoephedrine: Approx 2 hr.
Distribution: Pseudoephedrine may cross the placenta, enter CSF and distributed into breast milk. Volume of distribution: Acrivastine: Approx 0.5-0.8 L/kg; Pseudoephedrine: 2.64-3.51 L/kg. Plasma protein binding: Acrivastine: Approx 50% (mainly to albumin).
Metabolism: Acrivastine: Minimal hepatic metabolism. Pseudoephedrine: Undergoes N-demethylation to norpseudoephedrine (active metabolite).
Excretion: Acrivastine: Via urine (84%); faeces (13%). Pseudoephedrine: Via urine (43-96% as unchanged drug; 1-6% as norpseudoephedrine).
Store between 15-25°C.
MIMS Class
Antihistamines & Antiallergics
Anon. Acrivastine and Pseudoephedrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/09/2013.

Anon. Pseudoephedrine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 05/09/2013.

Anon. Pseudoephedrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/09/2013.

Buckingham R (ed). Acrivastine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/09/2013.

Buckingham R (ed). Pseudoephedrine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/09/2013.

McEvoy GK, Snow EK, Miller J et al (eds). Acrivastine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 05/09/2013.

Disclaimer: This information is independently developed by MIMS based on Acrivastine + Pseudoephedrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in